Loading...
XSHE300233
Market cap592mUSD
Jan 10, Last price  
11.45CNY
1D
-3.86%
1Q
-13.06%
Jan 2017
-53.02%
IPO
13.20%
Name

Shandong Jincheng Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300233 chart
P/E
24.86
P/S
1.23
EPS
0.46
Div Yield, %
1.92%
Shrs. gr., 5y
-0.51%
Rev. gr., 5y
3.30%
Revenues
3.54b
+0.93%
569,928,918584,608,999759,384,949788,420,535799,331,826908,713,1181,050,829,9731,178,560,3001,420,385,0192,788,037,1003,007,968,0492,794,819,3322,961,935,8343,138,454,2803,505,716,9623,538,312,459
Net income
175m
-36.09%
53,666,15781,347,792104,624,06655,991,12841,610,64364,596,722108,700,716170,977,251159,390,211286,304,084263,863,408203,285,1860107,984,095273,365,308174,709,358
CFO
664m
+159.78%
30,230,061105,624,585108,674,38862,690,63686,605,84993,921,980219,455,483207,917,945241,482,126151,829,060352,196,534577,983,378546,126,321437,185,450255,626,529664,075,132
Dividend
Sep 20, 20240.1 CNY/sh
Earnings
Apr 18, 2025

Profile

Shandong Jincheng Pharmaceutical Group Co., Ltd, together with its subsidiaries, researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally. The company offers active pharmaceutical ingredients, biopharmaceuticals, medical intermediates, fine chemicals, finished dosages, and pharmaceutical products. It also provides animal nutrition and health care, as well as CMO and CDMO services. The company was founded in 2004 and is based in Zibo, China.
URL
http://www.jinchengpharm.com/
IPO date
Jun 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,538,312
0.93%
3,505,717
11.70%
Cost of revenue
2,939,565
2,780,343
Unusual Expense (Income)
NOPBT
598,747
725,374
NOPBT Margin
16.92%
20.69%
Operating Taxes
32,097
60,092
Tax Rate
5.36%
8.28%
NOPAT
566,651
665,282
Net income
174,709
-36.09%
273,365
153.15%
Dividends
(83,520)
(76,477)
Dividend yield
1.31%
0.87%
Proceeds from repurchase of equity
56,936
BB yield
-0.65%
Debt
Debt current
94,000
377,201
Long-term debt
353,620
275,729
Deferred revenue
61,595
65,996
Other long-term liabilities
1
1
Net debt
(724,536)
(363,655)
Cash flow
Cash from operating activities
664,075
255,627
CAPEX
(342,899)
Cash from investing activities
(309,989)
Cash from financing activities
(243,311)
3,829
FCF
692,899
286,407
Balance
Cash
1,024,635
859,028
Long term investments
147,521
157,557
Excess cash
995,240
841,299
Stockholders' equity
1,289,048
1,311,965
Invested Capital
3,291,574
3,479,461
ROIC
16.74%
20.17%
ROCE
13.58%
16.31%
EV
Common stock shares outstanding
383,875
385,022
Price
16.66
-26.83%
22.77
-21.73%
Market cap
6,395,351
-27.05%
8,766,941
-21.85%
EV
5,737,741
8,455,160
EBITDA
910,410
981,139
EV/EBITDA
6.30
8.62
Interest
26,214
26,824
Interest/NOPBT
4.38%
3.70%